ConcertAI and the National Cancer Institute Community Oncology Research Program (NCI NCORP)-designated Louisiana State University (LSU) Health New Orleans have entered a five-year collaboration to boost clinical trial diversity.

The alliance will also aid in guaranteeing wider access to clinical trials throughout the Gulf South region.

The latest partnership complements the Engaging Research to Achieve Cancer Care Equality (ERACE) programme of ConcertAI. 

Leveraging real-world data (RWD) and advanced technologies, this programme provides all patients equitable access, care, and outcomes.

With a $5.6m NCI grant, LSU Health New Orleans could set up a clinical trials network in the Gulf South region. 

Following this, SLSU Health New Orleans received a $13.6m award from the NCI to extend the network, focusing on minority and underserved patients.

The partnership will analyse the Gulf South Minority Underserved NCORP programme’s impact on enrolling minority patients in trials, their retention and health outcomes using RWD from ConcertAI’s countrywide cancer care settings, and ‘system of evidence’, as well as LSU’s trial sites.

LSU Health New Orleans NCORP principal investigator Augusto Ochoa said: “The collaboration will identify current cancer care disparities in Louisiana and how they can be addressed. 

“Insights gleaned from the novel real-world data advanced by the partnership will lead to evidence-based strategies to reduce health inequities among populations with existing disparities, including the implementation of AI-based capabilities to improve patient screening, engagement, and recruitment at clinical trial sites throughout the region.”